Question 1

What is Gazyva?

Accepted Answer

Gazyva is a medication classified as a monoclonal antibody. It functions by targeting a specific protein known as CD20, which is located on the surface of certain white blood cells.

By binding to these proteins, the drug assists the immune system in locating and destroying the targeted cells. This mechanism is intended to interfere with the progression of cancer within the body.

Question 2

What is Gazyva used for?

Accepted Answer

Gazyva is used to treat chronic lymphocytic leukemia and follicular lymphoma .

Question 3

How does Gazyva work?

Accepted Answer

Mechanism of Action

Gazyva belongs to a class of medications known as monoclonal antibodies. It is specifically designed to recognize and attach to a protein called CD20, which is found on the surface of B-cells. B-cells are a type of white blood cell that can become cancerous in conditions such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).

When Gazyva attaches to the CD20 protein on these abnormal cells, it works in several ways to combat the cancer:

Immune System Recruitment: The medication acts as a flag, signaling the body's own immune system to identify, attack, and kill the cancerous B-cells.

Direct Cell Death: Gazyva can cause the cancerous cells to self-destruct directly upon attachment.

Cellular Destruction: It helps other specialized immune cells release substances that destroy the targeted cancer cells.

By targeting and reducing the number of these abnormal B-cells, Gazyva helps to slow or stop the progression of the disease. Because CD20 is also found on some healthy B-cells, the medication may also affect normal B-cells, though the body can typically produce new, healthy ones after treatment.

Question 4

What are the active ingredients in Gazyva?

Accepted Answer

The active ingredient in Gazyva is obinutzumab .

Question 5

What are the side effects of Gazyva?

Accepted Answer

Common side effects of Gazyva may include:

infusion reactions

fatigue

fever

and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Gazyva?

Accepted Answer

Gazyva belongs to the anti-CD20 monoclonal antibody drug class.

Question 7

What is the dosage of Gazyva and how do I take it?

Accepted Answer

How Gazyva is Administered

Gazyva is given as an infusion into a vein by a healthcare professional in a medical setting, such as a hospital or clinic. Because the medication can cause reactions during the infusion, the process is usually performed slowly and can take several hours to complete.

Treatment Schedule

This medication is typically administered in treatment cycles. During the first cycle, infusions are often given more frequently, such as several times over the first few weeks. In subsequent cycles, infusions are usually spaced further apart, occurring once every few weeks.

Before each infusion, your healthcare provider may give you other medications to help prevent or reduce the severity of infusion-related reactions. These premedications may include:

Pain or fever reducers

Antihistamines

Corticosteroids

Your doctor may also instruct you to drink plenty of water or receive intravenous fluids before your treatment to stay hydrated.

Missed Doses

If you miss an appointment for a Gazyva infusion, contact your healthcare provider immediately to reschedule. It is important to stay on the prescribed schedule to ensure the treatment is as effective as possible.

Question 8

Is Gazyva safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Gazyva can cause harm to a fetus when administered to a pregnant person. Healthcare providers typically recommend avoiding pregnancy while undergoing treatment with this medication.

Key considerations for pregnancy include:

Contraception: Individuals who can become pregnant should use effective birth control during treatment and for at least 6 months after the final dose of Gazyva.

Testing: A pregnancy test may be required before starting this medication to confirm that the patient is not pregnant.

Exposure: If pregnancy occurs during treatment or shortly after, it is important to contact a healthcare provider immediately to discuss potential risks to the fetus.

Breastfeeding

It is not known if Gazyva passes into breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions, breastfeeding is generally not recommended during treatment and for at least 6 months after the last dose. Patients should discuss feeding options with their medical team.

Question 9

What forms and strengths does Gazyva come in?

Accepted Answer

Administration Form

Gazyva is provided as a sterile, preservative-free liquid solution in a single-dose vial. It is a concentrated medication that must be diluted by a healthcare professional before it is used.

The medication is administered as an intravenous infusion, meaning it is delivered directly into a vein over a period of time. It is not available in oral forms such as tablets or capsules.

Question 10

What is the FDA approval status of Gazyva?

Accepted Answer

FDA Approval and Indications

Gazyva was first approved by the U.S. Food and Drug Administration (FDA) in November 2013. It is currently approved for the following indications:

Chronic Lymphocytic Leukemia (CLL): Used in combination with chlorambucil for patients who have not been previously treated.

Follicular Lymphoma (FL): Used in combination with bendamustine for patients whose cancer returned or did not respond to a previous treatment regimen that included rituximab.

Untreated Follicular Lymphoma: Used in combination with chemotherapy, followed by Gazyva monotherapy, for patients with previously untreated Stage II bulky, III, or IV follicular lymphoma.

Boxed Warnings

The FDA has issued a boxed warning for Gazyva due to the risk of two serious conditions:

Hepatitis B Virus (HBV) Reactivation: In patients who have previously had hepatitis B, the virus can become active again during or after treatment with Gazyva. This reactivation can lead to severe liver damage, liver failure, or death. Healthcare providers typically screen for HBV infection before starting treatment.

Progressive Multifocal Leukoencephalopathy (PML): This is a rare but serious brain infection caused by a virus. It can lead to severe disability or death. Patients are monitored for any new or worsening neurological symptoms while receiving this medication.

Question 11

What should I know about Gazyva and cost?

Accepted Answer

Factors Affecting Cost

Gazyva is a brand-name biologic medication. The total cost of treatment can vary significantly based on several factors:

Insurance coverage: Your out-of-pocket costs will depend on whether your insurance plan covers the drug and what your specific copay or coinsurance requirements are.

Treatment schedule: The number of doses and the length of your treatment course will affect the overall price.

Administration fees: Because Gazyva is given as an intravenous infusion in a medical setting, you will likely face costs for the facility and the healthcare professionals who administer the drug.

Biosimilar Availability

There are currently no biosimilar versions of Gazyva. Biologics like Gazyva are made from living cells, making them more complex and expensive to produce than standard chemical drugs. Without a biosimilar alternative, the price of the brand-name drug typically remains high.

Financial Assistance

The manufacturer offers support services to help patients navigate the cost of Gazyva. This may include copay assistance for those with commercial insurance or patient assistance programs for individuals who meet certain financial criteria or lack insurance coverage. You can speak with your healthcare provider or a financial counselor at your treatment center to explore these options.

Gazyva

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?